aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Artizan Biosciences, a Durham-based biotech firm, specializes in the development of small molecule drugs for pharmaceutical applications. The company focuses on drug discovery and development services aimed at creating treatments for human use.
Artizan Biosciences has made significant strides in the biotech industry, contributing to advancements in pharmaceutical drug development. The company's impact is notable in its specialized approach to creating small molecule drugs, positioning it as a key player in the biotech sector.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Development
Technology
Biotech
Model Types
Professional Services, Software
Revenue Type(s)
Consulting
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Artizan Biosciences founded?
Artizan Biosciences was founded in 2016.
Where is Artizan Biosciences’s headquarters located?
Artizan Biosciences’s headquarters is located in Durham, NC, US.
When was Artizan Biosciences’s last funding round?
Artizan Biosciences’s most recent funding round was for $18.9M (USD) in March 2021.
How many employees does Artizan Biosciences have?
Artizan Biosciences has 26 employees as of Feb 5, 2024.
How much has Artizan Biosciences raised to-date?
As of July 05, 2023, Artizan Biosciences has raised a total of $33.9M (USD) since Mar 1, 2021.
Add Comparison
Total Raised to Date
$33.9M
USD
Last Update Mar 1, 2021
Last Deal Details
$18.9M
USD
Mar 1, 2021
Series A
Total Employees Over Time
26
As of Feb 2024
Artizan Biosciences Address
280 S Mangum St
suite 350
Durham,
North Carolina
27701
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts